ConductScience.org, home

Paper · 36545708

References75

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112673442Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).J Gastroenterol2003https://conductscience.org/library/papers/12673442PubMed
235464283Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition).Hepatobiliary Surg Nutr2022https://conductscience.org/library/papers/35464283PubMed
335978604
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma.
Liver Cancer2022https://conductscience.org/library/papers/35978604PubMed
429628281EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.J Hepatol2018https://conductscience.org/library/papers/29628281PubMed
533877527Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.Hepatol Int2021https://conductscience.org/library/papers/33877527PubMed
634143971Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.Lancet Oncol2021https://conductscience.org/library/papers/34143971PubMed
726146815World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma.Hepatology2015https://conductscience.org/library/papers/26146815PubMed
830665869Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol2019https://conductscience.org/library/papers/30665869PubMed
922105822Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma.J Clin Oncol2011https://conductscience.org/library/papers/22105822PubMed
1033317248Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects.Clin Mol Hepatol2021https://conductscience.org/library/papers/33317248PubMed
1133653656
Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization.
Acad Radiol2021https://conductscience.org/library/papers/33653656PubMed
1219725152Indicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patients.World J Gastroenterol2009https://conductscience.org/library/papers/19725152PubMed
1329420221Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study.Clin Cancer Res2018https://conductscience.org/library/papers/29420221PubMed
1412479938Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis.Hepatol Res2002https://conductscience.org/library/papers/12479938PubMed
1534754838Chemoembolization Plus Microwave Ablation vs Chemoembolization Alone in Unresectable Hepatocellular Carcinoma Beyond the Milan Criteria: A Propensity Scoring Matching Study.J Hepatocell Carcinoma2021https://conductscience.org/library/papers/34754838PubMed
1634185551Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.J Clin Oncol2021https://conductscience.org/library/papers/34185551PubMed
1735284529
Associating liver partition and portal vein ligation for staged hepatectomy versus sequential transarterial chemoembolization and portal vein embolization in staged hepatectomy for HBV-related hepatocellular carcinoma: a randomized comparative study.
Hepatobiliary Surg Nutr2022https://conductscience.org/library/papers/35284529PubMed
1832897657Graft Programmed Death Ligand 1 Expression as a Marker for Transplant Rejection Following Anti-Programmed Death 1 Immunotherapy for Recurrent Liver Tumors.Liver Transpl2021https://conductscience.org/library/papers/32897657PubMed
1929624699Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.Hepatology2018https://conductscience.org/library/papers/29624699PubMed
2029995681Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Unresectable Hepatitis B Virus-related Hepatocellular Carcinoma: A Single Center Study of 45 Patients.Ann Surg2020https://conductscience.org/library/papers/29995681PubMed

papers-2026-11-12-0.1.0

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/papers/v1/36545708/references